Is Foundayo Available on the NHS? Cost and Access Explained
Why MHRA approval doesn't mean NHS availability, what actually determines the cost of private treatment, what a proper assessment involves, and how to avoid unsafe sellers.
Part of the Overweight and Obesity condition guide.
This page changes quickly. UK pricing and supply were still settling at the time of writing, and NICE hasn't yet appraised the medicine. Check the review date above and treat any figure you see quoted online—here or elsewhere—with appropriate caution.
Foundayo on Private Prescription
Access Doctor provides Foundayo (orforglipron) following a GPhC-regulated online consultation with our pharmacist independent prescribers. Consultation included; your price is shown before you pay.
Order Foundayo →Why MHRA approval isn't NHS availability
No—not currently.
Foundayo (orforglipron) was authorised by the MHRA on 10 August 2026, making the UK the first country in Europe to license an oral GLP-1 for weight management and type 2 diabetes. Authorisation and availability are two different things, and the gap between them is where most of the confusion sits.
| Body | What it decides | Status for orforglipron |
|---|---|---|
| MHRA | Whether a medicine is safe, effective and of adequate quality | Decision made—authorised 10 August 2026 |
| NICE | Whether the NHS in England should fund it, weighing clinical benefit against cost | No technology appraisal published |
| SMC, AWMSG, DoH NI | NHS funding in Scotland, Wales and Northern Ireland | Separate processes, separate timelines |
Appraisals for new medicines commonly take 12 to 18 months from marketing authorisation, and NHS rollout—if the recommendation is positive—follows after that, usually with access prioritised for patients meeting stricter clinical criteria than the licence alone.
What this means in practice: anyone accessing Foundayo in the UK at present is doing so privately. By contrast, injectable tirzepatide is available on the NHS under NICE TA1026 on a phased rollout—which is covered in Foundayo vs Mounjaro.
What determines the cost of private treatment
Eli Lilly hadn't confirmed a UK list price at the time of writing. Any specific monthly figure circulating online should be treated as an estimate rather than a confirmed price.
For context rather than prediction, US pricing has been reported in the region of $25 to $149 per month depending on insurance status and access route, with self-pay figures reported higher. UK pricing is set through an entirely different mechanism, and these figures aren't a reliable guide to what UK patients will pay.
The four things you're paying for
If you're looking at private treatment, the medicine price is only part of it. A total cost typically includes:
- The medicine itself, which usually varies by dose—higher strengths generally cost more, so the cost of treatment tends to rise as you move up the titration schedule
- The prescriber consultation, initial and any follow-ups
- Ongoing monitoring and support, which some services bundle and others charge separately
- Delivery
When comparing services, compare the total annual cost at a realistic maintenance dose, not the entry price at the 0.8 mg starting dose. A headline price based on the lowest strength isn't what you'll be paying in six months.
What a proper assessment should involve
Foundayo is a prescription-only medicine (POM). It can't lawfully be sold without a prescription from a registered prescriber, and it can only be dispensed by a registered pharmacy.
A proper assessment should involve:
1
A clinical consultation
With a GP, pharmacist independent prescriber or other registered prescriber.
2
Verification of your BMI
Measured or independently confirmed, not simply self-declared.
3
A full medical history
Including thyroid conditions, family history of medullary thyroid cancer or MEN 2, pancreatitis, gastrointestinal conditions, kidney and liver function, eating disorder history and mental health.
4
A full medicines review
Including over-the-counter products, herbal remedies and supplements—St John's wort in particular interacts with orforglipron.
5
A decision on whether treatment is appropriate
Which will sometimes be no.
6
Follow-up before each dose increase
Rather than automatic escalation on a fixed calendar.
This is what good practice looks like, rather than a description of any one service—how ordering actually works at Access Doctor, including delivery and repeat supply, is set out on the weight loss treatment page. The GPhC expects online prescribing of weight-management medicines to include independent verification of the information a patient provides. A service that prescribes on the basis of a tick-box form alone, with no identity or BMI verification and no way to contact your GP, isn't meeting the standard—and that should concern you as a patient, not reassure you as a customer.
Who the UK licence covers
The UK licence covers:
- Adults with a BMI of 30 kg/m² or above, alongside diet and exercise
- Adults with a BMI of 27 to under 30 kg/m² with at least one weight-related condition
- Adults with type 2 diabetes needing better glycaemic control
Meeting the BMI threshold doesn't by itself mean the medicine is appropriate for you. If you're not sure where you sit, our BMI calculator is a starting point, and the safety guide sets out who shouldn't take Foundayo at all.
How to spot an unsafe seller
The MHRA has explicitly warned that buying GLP-1 medicines from unregulated sellers carries serious health risks. Counterfeit weight-loss medicines have been seized in the UK, and demand for a newly launched product creates exactly the conditions in which fakes circulate.
Before buying from any online service, check
- The pharmacy appears on the GPhC register at pharmacyregulation.org and displays its registration number
- The prescriber is registered with the GMC, GPhC, NMC or another appropriate regulator, and is named
- There is a genuine consultation, not just a form
- The service asks about your medical history and is willing to say no
- The medicine is supplied in original, sealed, UK-labelled packaging with a patient information leaflet
Treat as red flags
No prescription required, or a "consultation" that can't result in refusal. Prices far below everyone else. Sales through social media, messaging apps or marketplace listings. Unbranded, unsealed or foreign-labelled packaging. No named pharmacy, no UK address, no way to contact a human. Pressure to buy multiple months upfront. Compounded or "generic orforglipron"—there's no legitimate generic version of a medicine still under patent, and compounded GLP-1 products have been associated with dosing errors and harm.
If Foundayo isn't the right route
Foundayo is one option among several, and for some people it won't be the best value or the best clinical fit.
| Option | Route | NHS availability | Worth considering if |
|---|---|---|---|
| Foundayo (orforglipron) | Daily tablet | No | You want a tablet with no fasting or water rules |
| Wegovy tablets | Daily tablet, fasted | No | Greater average weight loss matters more than routine |
| Mounjaro (tirzepatide) | Weekly injection | Yes, phased under NICE TA1026 | You meet the NICE criteria, or want the largest average effect |
| NHS weight management services | Lifestyle, with medicines where eligible | Yes | Cost is the main barrier to private treatment |
The first question worth asking a prescriber isn't which private option is cheapest, but whether you meet the NICE TA1026 criteria for NHS tirzepatide—a BMI of at least 35, or 32.5 for people of South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean background, plus at least one weight-related condition. That answer reframes everything else.
Check Whether Foundayo Is Right for You
Reviewed by a GPhC-registered pharmacist independent prescriber, with BMI and medical history checked properly. There's no obligation to order, and no medicine is supplied where treatment isn't clinically appropriate.
Order Foundayo →Frequently Asked Questions
Is Foundayo available on the NHS?
No, not currently. MHRA authorisation decides whether a medicine is safe, effective and of adequate quality, while NICE decides separately whether the NHS in England should fund it. NICE has not yet published a technology appraisal for orforglipron, and appraisals for new medicines commonly take 12 to 18 months from marketing authorisation. Anyone accessing Foundayo in the UK at present is doing so privately.
Can my GP prescribe Foundayo?
NHS prescribing follows NICE guidance, which does not yet exist for this medicine, so your GP is unlikely to be able to prescribe it on the NHS at present. GPs can issue private prescriptions but are not obliged to, and many practices have a policy of not doing so for weight management medicines. A registered online pharmacy with prescribers is the usual private route.
What does Foundayo cost in the UK?
Eli Lilly had not confirmed a UK list price at the time of writing, so any specific monthly figure circulating online should be treated as an estimate rather than a confirmed price. Private treatment costs usually combine the medicine, which varies by strength, the prescriber consultation, ongoing monitoring and delivery. When comparing services, compare the total annual cost at a realistic maintenance dose rather than the entry price at the 0.8mg starting dose.
Will Foundayo be cheaper than injectable GLP-1 medicines?
That is not confirmed. Tablets can be cheaper to manufacture and distribute than injectables, and a daily tablet avoids the cold chain that pre-filled pens require, but UK pricing had not been announced at the time of writing. Do not assume the tablet will be the cheaper option, particularly against injectable medicines that have been on the market longer and face more competition.
Can I switch from Mounjaro or Wegovy to Foundayo?
That is a clinical decision for your prescriber, who will advise on timing and on the appropriate starting dose. Do not take Foundayo alongside another GLP-1 receptor agonist. Bear in mind that injectable tirzepatide produced roughly double the average weight loss of orforglipron in their respective trials, so switching from an injection to a tablet may mean accepting a smaller result in exchange for convenience.
Is Foundayo covered by private health insurance?
Most UK private medical insurance policies exclude weight management medicines, so in most cases it will not be covered. Check your policy documents or contact your insurer directly before assuming any part of the cost will be reimbursed.
Can I get Foundayo on prescription in Scotland, Wales or Northern Ireland?
The MHRA licence is UK-wide, so the medicine can lawfully be prescribed privately anywhere in the UK. NHS funding decisions are devolved and are made separately by the Scottish Medicines Consortium, the All Wales Medicines Strategy Group and the Department of Health in Northern Ireland, so those bodies may reach different conclusions on different timelines.
How do I know an online pharmacy selling Foundayo is legitimate?
Check that the pharmacy appears on the General Pharmaceutical Council register and displays its registration number, that the prescriber is named and registered with an appropriate regulator, and that there is a genuine consultation that can result in a refusal. The medicine should arrive in original sealed UK-labelled packaging with a patient information leaflet. Treat no-prescription sales, prices far below everyone else, social media selling and pressure to buy several months upfront as red flags.
How Access Doctor supplies Foundayo
Access Doctor is the trading name for Pharmadocs UK Ltd, a GPhC-registered online pharmacy (registration number 9011198). Prescriptions are issued by pharmacist independent prescribers after a clinical assessment, medicines are dispensed from our UK pharmacy in original sealed packaging with the patient information leaflet, and delivery is discreet. If treatment isn't clinically appropriate, we'll tell you rather than supply it.
Weight Loss · Rx
Foundayo (Orforglipron)
Once-daily GLP-1 tablet. Free online consultation; your price is confirmed before payment.
View product →Weight Loss · Rx
Wegovy Tablets
Oral semaglutide, the other licensed GLP-1 tablet, with a published UK price.
View product →Compare the full range of weight loss treatments, including injections, before deciding.
References
- Medicines and Healthcare products Regulatory Agency. UK first in Europe to authorise orforglipron for weight management and type 2 diabetes. 10 August 2026. gov.uk
- The Pharmaceutical Journal. MHRA approves orforglipron weight-loss pill. 2026. pharmaceutical-journal.com
- General Pharmaceutical Council. Updated enforcement notice issued on weight management prescription medicine ads. pharmacyregulation.org
- The Pharmaceutical Journal. Staying safe with online pharmacies: what patients and providers need to know about weight-loss prescribing. pharmaceutical-journal.com
- NHS England. Interim commissioning guidance: NICE TA1026 tirzepatide. england.nhs.uk
Medical disclaimer: This article is for informational purposes only and does not constitute medical advice, nor an offer to supply any medicine. Prices and availability are subject to change. Always consult a qualified healthcare professional for diagnosis and treatment. In a medical emergency, call 999.